{"id":525776,"date":"2025-09-03T00:00:00","date_gmt":"2025-09-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfhe0001-2025-biopharma-beta-thalassemia-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5\/"},"modified":"2026-04-18T23:10:36","modified_gmt":"2026-04-18T23:10:36","slug":"nrlfhe0001-2025-biopharma-beta-thalassemia-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfhe0001-2025-biopharma-beta-thalassemia-landscape-forecast-niche-rare-disease-landscape-forecast-us-eu5\/","title":{"rendered":"Beta Thalassemia &#8211; Landscape &#038; Forecast &#8211; Niche &#038; Rare Disease Landscape &#038; Forecast (US\/EU5)"},"content":{"rendered":"<p>Beta thalassemia (<abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr>) is a rare genetic disorder characterized by the reduced production of hemoglobin. <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> minor is caused by a mutation in one hemoglobin beta (<abbr data-abbreviation-entity=\"8220\" title=\"hemoglobin subunit beta\">HBB<\/abbr>) gene, and transfusion-dependent (<abbr data-abbreviation-entity=\"5907\" title=\"transfusion-dependent\">TD<\/abbr>)\u00a0thalassemia is caused by a mutation in both <abbr data-abbreviation-entity=\"8220\" title=\"hemoglobin subunit beta\">HBB<\/abbr> genes, although some patients with mutations in both genes are classified as having non-transfusion-dependent (<abbr data-abbreviation-entity=\"8217\" title=\"non-transfusion-dependent\">NTD<\/abbr>) thalassemia. Patients can present with jaundice, bone deformities, and chronic anemia. Management of <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> was once limited to regular blood transfusions and iron chelators, but therapies such as <abbr data-abbreviation-entity=\"5794\" title=\"Bristol Myers Squibb\">BMS<\/abbr>\u2019s Reblozyl, Bluebird Bio\u2019s Zynteglo, and Vertex \/ CRISPR Therapeutics\u2019 Casgevy now offer a more promising future for <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> patients. Nevertheless,\u00a0strong unmet need remains for universally curative therapies that improve <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> patients\u2019 quality of life. In this report, we examine the current treatment of <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> in the United States and <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> countries and the agents in development, including those that target the underlying genetic defect and reduce the transfusion burden.<\/p>\n<p>Questions answered<\/p>\n<ul class=\"round-bullets\">\n<li>How large is the diagnosed <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> population in the United States and <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>? How will the population change through 2034?<\/li>\n<li>What is the current landscape for <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr> patients, and how will it change over the next 10 years considering alternative therapies, such as Zynteglo and Casgevy, are now available?<\/li>\n<li>What pipeline products are most promising, and what sales \/ uptake could they secure in <abbr data-abbreviation-entity=\"10720\" title=\"beta thalassemia\">BT<\/abbr>? How will emerging therapies affect medical practice?<\/li>\n<\/ul>\n<p>Product description<\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><b>Publication date <\/b>September 2025<\/p>\n<p><b>Geography <\/b>United States, <abbr data-abbreviation-entity=\"6092\" title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>Primary research<\/strong><\/p>\n<p>Country-specific interviews with thought-leading hematologists<\/p>\n<p>Survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology<\/strong><\/p>\n<p>Diagnosed prevalent and drug-treatable cases of beta thalassemia by country, segmented by severity, genotype, and availability of <abbr data-abbreviation-entity=\"10736\" title=\"human leukocyte antigen\">HLA<\/abbr>-matched sibling HSCT donor<\/p>\n<p><strong>Forecast<\/strong><\/p>\n<p>Drug-level sales and patient share of key beta thalassemia therapies in 2024 and 2034<\/p>\n<p><strong>Drug treatments<\/strong><\/p>\n<p>Coverage of key current and late-phase emerging therapies<\/p>\n","protected":false},"template":"","class_list":["post-525776","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525776","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525776\/revisions"}],"predecessor-version":[{"id":575737,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/525776\/revisions\/575737"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=525776"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}